Science Explorer Back to mapMap
Discussion
Institution · NewLink Genetics (United States)

Most cited papers from NewLink Genetics (United States)

NewLink Genetics (United States)

What are the most cited papers from NewLink Genetics (United States)?

The most cited paper from NewLink Genetics (United States) is "ICTV Virus Taxonomy Profile: Flaviviridae" (Peter Simmonds, Paul Becher, Jens Bukh et al., 2017), with 866 citations. Next come "Aryl hydrocarbon receptor control of a disease tolerance defence pathway" (687) and "Epidemic arboviral diseases: priorities for research and public health" (595).

Showing 50 of 60 papers. Every paper with more than 41 citations is listed.

Most cited papers, sortable by citations and release date
#Paper
1 ICTV Virus Taxonomy Profile: Flaviviridae Peter Simmonds, Paul Becher, Jens Bukh et al. · Journal of General Virology Open access 2017 866
2 Aryl hydrocarbon receptor control of a disease tolerance defence pathway Alban Bessede et al. · Nature Open access 16 Jun 2014 687
3 Epidemic arboviral diseases: priorities for research and public health Annelies Wilder‐Smith, Duane J. Gubler, Scott C. Weaver et al. · The Lancet Infectious Diseases 20 Dec 2016 595
4 Inhibition of Indoleamine 2,3-Dioxygenase in Dendritic Cells by Stereoisomers of 1-Methyl-Tryptophan Correlates with Antitumor Responses De-Yan Hou, Alexander J. Muller, Madhav D. Sharma et al. · Cancer Research 15 Jan 2007 588
5 Indoleamine 2,3-dioxygenase pathways of pathogenic inflammation and immune escape in cancer George C. Prendergast, Courtney Smith, Sunil Thomas et al. · Cancer Immunology Immunotherapy Open access 7 Apr 2014 495
6 Global Biobank Meta-analysis Initiative: Powering genetic discovery across human disease Wei Zhou et al. · Cell Genomics Open access152 authors Oct 2022 437
7 A Recombinant Vesicular Stomatitis Virus Ebola Vaccine Jason A. Regules et al. · New England Journal of Medicine Open access 2 Apr 2015 397
8 IDO inhibits a tryptophan sufficiency signal that stimulates mTOR: A novel IDO effector pathway targeted by D-1-methyl-tryptophan Richard A. Metz, Sonja Rust, James B. DuHadaway et al. · OncoImmunology Open access 6 Sep 2012 385
9 Proposed revision to the taxonomy of the genus Pestivirus, family Flaviviridae Donald B. Smith, Gregor Meyers, Jens Bukh et al. · Journal of General Virology Open access Aug 2017 338
10 NCCN Guidelines Insights: Ovarian Cancer, Version 1.2019 Deborah Kay Armstrong et al. · Journal of the National Comprehensive Cancer Network Open access Aug 2019 334
11 IDO Is a Nodal Pathogenic Driver of Lung Cancer and Metastasis Development Courtney Smith, Mee Young Chang, Katherine H. Parker et al. · Cancer Discovery Open access 20 Jul 2012 327
12 Trial watch: IDO inhibitors in cancer therapy Erika Vacchelli, Fernando Pardo Aranda, Alexander M.M. Eggermont et al. · OncoImmunology Open access Sep 2014 326
13 Amino acid catabolism: a pivotal regulator of innate and adaptive immunity Tracy L. McGaha, Lei Huang, Henrique de Paula Lemos et al. · Immunological Reviews ReviewOpen access 14 Aug 2012 204
14 Dose Escalation Trial of the Wee1 Inhibitor Adavosertib (AZD1775) in Combination With Gemcitabine and Radiation for Patients With Locally Advanced Pancreatic Cancer Kyle Clifford Cuneo, Meredith Ann Morgan, Vaibhav Sahai et al. · Journal of Clinical Oncology Open access 9 Aug 2019 203
15 IDO2 is critical for IDO1-mediated T-cell regulation and exerts a non-redundant function in inflammation Richard A. Metz, Courtney Smith, James B. DuHadaway et al. · International Immunology Open access 9 Jan 2014 193
16 Antimicrobial Activity of a Novel Catheter Lock Solution Chirag Shah, Marc W. Mittelman, John William Costerton et al. · Antimicrobial Agents and Chemotherapy Open access Jun 2002 187
17 A key in vivo antitumor mechanism of action of natural product-based brassinins is inhibition of indoleamine 2,3-dioxygenase Tinku Banerjee, James B. DuHadaway, Paul M. Gaspari et al. · Oncogene 19 Nov 2007 174
18 A first in man phase I trial of the oral immunomodulator, indoximod, combined with docetaxel in patients with metastatic solid tumors Hatem Hussein Soliman, Erica L. Jackson, Tony Neuger et al. · Oncotarget Open access 30 Sep 2014 174
19 The PTEN pathway in T regs is a critical driver of the suppressive tumor microenvironment Madhav D. Sharma, Rahul Suresh Shinde, Tracy L. McGaha et al. · Science Advances Open access 6 Nov 2015 172
20 Phase Ia study of the indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor navoximod (GDC-0919) in patients with recurrent advanced solid tumors Asha Nayak-Kapoor et al. · Journal for ImmunoTherapy of Cancer Open access 19 Jun 2018 158
21 A phase I study of indoximod in patients with advanced malignancies Hatem Hussein Soliman, Susan E. Minton, Hyo Sook Han et al. · Oncotarget Open access 20 Mar 2016 145
22 IDO2 in Immunomodulation and Autoimmune Disease George C. Prendergast, Richard A. Metz, Alexander J. Muller et al. · Frontiers in Immunology Open access 20 Nov 2014 133
23 Safety and immunogenicity of the rVSV∆G-ZEBOV-GP Ebola virus vaccine candidate in healthy adults: a phase 1b randomised, multicentre, double-blind, placebo-controlled, dose-response study D. Gray Heppner et al. · The Lancet Infectious Diseases Open access 10 Jun 2017 122
24 IDO2 Is a Critical Mediator of Autoantibody Production and Inflammatory Pathogenesis in a Mouse Model of Autoimmune Arthritis Lauren M.F. Merlo, Elizabeth Pigott, James B. DuHadaway et al. · The Journal of Immunology Open access Feb 2014 121
25 Embryonic Stem Cells As an Alternate Marrow Donor Source Richard K. Burt, Larissa Verda, Duck-An Kim et al. · The Journal of Experimental Medicine Open access 29 Mar 2004 111
26 Molecular Methods and Platforms for Infectious Diseases Testing Rajyasree Emmadi, Jerry Boonyaratanakornkit, Rangaraj Selvarangan et al. · Journal of Molecular Diagnostics Open access 27 Aug 2011 107
27 Induction of IDO-1 by Immunostimulatory DNA Limits Severity of Experimental Colitis Matthew A. Ciorba, Ellen E. Bettonville, Keely G. McDonald et al. · The Journal of Immunology Open access 25 Feb 2010 105
28 Phase II trial of the IDO pathway inhibitor indoximod plus pembrolizumab for the treatment of patients with advanced melanoma Yousef Zakharia, Robert R. McWilliams, Olivier Rixe et al. · Journal for ImmunoTherapy of Cancer Open access Jun 2021 98
29 A Phase 3 Randomized Clinical Trial of Chemotherapy With or Without Algenpantucel-L (HyperAcute-Pancreas) Immunotherapy in Subjects With Borderline Resectable or Locally Advanced Unresectable Pancreatic Cancer Daniel Brock Hewitt et al. · Annals of Surgery 22 Dec 2020 96
30 Indoleamine 2,3-dioxygenase as a Modifier of Pathogenic Inflammation in Cancer and other Inflammation-Associated Diseases G C Prendergast, Mee Young Chang, Laura Mandik‐Nayak et al. · Current Medicinal Chemistry Open access May 2011 96
31 Yellow Fever Remains a Potential Threat to Public Health Pedro F.C. Vasconcelos, Thomas P. C. Monath · Vector-Borne and Zoonotic Diseases 11 Jul 2016 92
32 Emergency Postexposure Vaccination With Vesicular Stomatitis Virus–Vectored Ebola Vaccine After Needlestick Lilin Lai, Richard T. Davey, Allison Beck et al. · JAMA Open access 5 Mar 2015 92
33 Protein-RNA interface residue prediction using machine learning: an assessment of the state of the art Rasna R. Walia, Cornelia Caragea, Benjamin A. Lewis et al. · BMC Bioinformatics Open access 10 May 2012 89
34 rVSVΔG-ZEBOV-GP (also designated V920) recombinant vesicular stomatitis virus pseudotyped with Ebola Zaire Glycoprotein: Standardized template with key considerations for a risk/benefit assessment Thomas P. C. Monath, Patricia Fast, Kayvon Modjarrad et al. · Vaccine X Open access 30 Jan 2019 85
35 Discovery of Clinical Candidate (1R,4r)-4-((R)-2-((S)-6-Fluoro-5H-imidazo[5,1-a]isoindol-5-yl)-1-hydroxyethyl)cyclohexan-1-ol (Navoximod), a Potent and Selective Inhibitor of Indoleamine 2,3-Dioxygenase 1 Sanjeev Kumar, Jesse P. Waldo, Firoz Ali Jaipuri et al. · Journal of Medicinal Chemistry Open access 18 Jun 2019 83
36 Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study Angela Huttner et al. · The Lancet Infectious Diseases Open access 5 Apr 2018 83
37 Approval of Raxibacumab for the Treatment of Inhalation Anthrax Under the US Food and Drug Administration “Animal Rule” Chiawei W. Tsai, Stephen Morris · Frontiers in Microbiology Open access Dec 2015 83
38 Assessing the safety and immunogenicity of recombinant vesicular stomatitis virus Ebola vaccine in healthy adults: a randomized clinical trial May S. ElSherif et al. · Canadian Medical Association Journal Open access 18 Jun 2017 80
39 A replication-incompetent Rift Valley fever vaccine: Chimeric virus-like particles protect mice and rats against lethal challenge Robert B. Mandell, Ramesh Koukuntla, Laura J.K. Mogler et al. · Virology Open access 27 Nov 2009 80
40 Effective Treatment of Preexisting Melanoma with Whole Cell Vaccines Expressing α(1,3)-Galactosyl Epitopes Gabriela R. Rossi, Mario R. Mautino, Robert C. Unfer et al. · Cancer Research 15 Nov 2005 76
41 Towards a Genetic Definition of Cancer-Associated Inflammation George C. Prendergast, Richard A. Metz, Alexander J. Muller · American Journal Of Pathology Open access 12 Mar 2010 75
42 Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash Neelima N. Nallapaneni, Rajesh Mourya, Vijaya Raj Bhatt et al. · Journal of the National Comprehensive Cancer Network Open access Aug 2014 74
43 The SOCS3-Independent Expression of IDO2 Supports the Homeostatic Generation of T Regulatory Cells by Human Dendritic Cells Sara Trabanelli, Darina Očadlíková, Marilena Ciciarello et al. · The Journal of Immunology Open access 4 Jan 2014 69
44 A dose-dependent plasma signature of the safety and immunogenicity of the rVSV-Ebola vaccine in Europe and Africa Angela Huttner, Christophe Combescure, Stéphane Grillet et al. · Science Translational Medicine Open access 12 Apr 2017 65
45 Immunotherapeutic Suppression of Indoleamine 2,3-Dioxygenase and Tumor Growth with Ethyl Pyruvate Alexander J. Muller, James B. DuHadaway, Daniel Jaller et al. · Cancer Research Open access 16 Feb 2010 64
46 Concurrent whole brain radiotherapy and short-course chloroquine in patients with brain metastases: a pilot trial Harriet Eldredge-Hindy, Albert S. DeNittis, James B. DuHadaway et al. · Journal of Radiation Oncology Open access 15 Aug 2013 60
47 Adjunctive Antibiotic/Anticoagulant Lock Therapy in the Treatment of Bacteremia Associated with the Use of a Subcutaneously Implanted Hemodialysis Access Device Rajesh Boorgu, Alan J. Dubrow, Nathan W. Levin et al. · ASAIO Journal Nov 2000 56
48 Perturbed myoepithelial cell differentiation in BRCA mutation carriers and in ductal carcinoma in situ Lina Ding et al. · Nature Communications Open access 13 Sep 2019 54
49 Immunogenicity, Lot Consistency, and Extended Safety of rVSVΔG-ZEBOV-GP Vaccine: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study in Healthy Adults Scott A. Halperin, Rituparna Das, Matthew T. Onorato et al. · The Journal of Infectious Diseases Open access 17 May 2019 54
50 Yellow fever vaccine supply: a possible solution Thomas P. C. Monath, Jack Woodall, Duane J. Gubler et al. · The Lancet Apr 2016 54

Citations are OpenAlex's own counts, from its 2026-09-23 snapshot, so the ranking can differ from Google Scholar or Web of Science. A paper is listed for an institution when any of its authors gave it as an affiliation; retracted papers and papers whose citation count cannot be traced to citing works are left out, and a preprint and the article it became are shown once. Release dates are OpenAlex's: where a source gave only a month or a year, that is what is shown. How the lists are chosen.